NMPA Releases 58th Batch of Reference Drugs for Generic Quality Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 58th batch of reference drugs for...
Drug
Alphamab/3DMed’s Envafolimab Gains FDA Fast-Track Status for Sarcoma Treatment
Alphamab Oncology (HKG: 9966) and 3D Medicines’ envafolimab (KN035) has obtained fast-track status from the...
Suzhou Zelgen Completes Phase II Study of Jakinib for Ankylosing Spondylitis
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced the successful completion of a multi-center, randomized...
Buchang Pharmaceuticals Gains NMPA Approval for BC008-1A Clinical Study
China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) announced that it has received approval from...
CDE Prioritizes Review of Pearl Bio’s Breatinib for NSCLC Treatment
The Center for Drug Evaluation (CDE) website indicates that Beijing Pearl Biotechnology Co., Ltd’s APL-101/PLB1001...
Jiangsu Hengrui Medicine Gains NMPA Approval for HRS-6209 Clinical Study
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from...
I-Mab’s Lemzoparlimab Gains CDE Approval for HR-MDS Phase III Trial
China-based I-Mab (NASDAQ: IMAB) announced that it has successfully completed an End-of-Phase 2 (EoP2) meeting...
Takeda’s Modakafusp Alfa and TAK-981 Gain NMPA Clinical Trial Approvals
The National Medical Products Administration (NMPA) website indicates that Japan-based Takeda Pharmaceutical Co., Ltd’s (TYO:...
Huahai Pharmaceutical Gains FDA Approval for Generic Fingolimod
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received Abbreviated New...
Luye Pharma’s LY03015 Receives FDA Approval for Phase I Clinical Study
China-based Luye Pharma Group (HKG: 2186) announced that it has received approval from the US...
InnoCare Pharma’s BCL2 Inhibitor ICP-248 Gains NMPA Approval for Clinical Study
China’s Beijing InnoCare Pharma (HKG: 9969) announced that it has received approval from the National...
BeiGene’s Tislelizumab Meets Primary Endpoint in HCC Study at ESMO
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) presented the latest results of the global Phase...
Luye Pharma’s BA-CovMab Receives NMPA Approval for COVID-19 Clinical Trials
China-based Luye Pharma Group (HKG: 2186) announced that its subsidiary Shandong BoAn Biotechnology Co., Ltd’s...
Transcenta’s TST001 Shows Promise in Gastric Cancer Trial with 73.3% Response Rate
China-based biotech Transcenta Holdings Ltd (HKG: 6628) announced interim safety and efficacy data from a...
CSPC Pharmaceutical’s TG103 Gains NMPA Approval for NASH and Alzheimer’s Trials
China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) announced that it has received approval from...
Jingxin Pharmaceutical Receives NMPA Approval for JBPOS0101 and JX7002 Trials
Jingxin Pharmaceutical Co., Ltd (SHE: 002020) announced that it has received clinical trial approvals from...
China’s Retail Pharmacy O2O Sales Surge to USD 2.9B in 2021
According to the “China Retail Pharmacy O2O Development Report” released by Minenet, the “online drug...
China’s Cecolin HPV Vaccine Shows 100% Efficacy in 66-Month Study
Chinese researchers have published 66-month follow-up data from a Phase III clinical study for the...
Dizal Pharma’s Sunvozertinib Gains NMPA Approval for EGFR Mutation NSCLC Trial
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced that it has received clinical trial approval...
Keymed and Lepu’s CMG901 Receives Breakthrough Therapy Designation for Gastric Cancer
The Center for Drug Evaluation (CDE) website indicates that CMG901, a Claudin 18.2 (CLDN18.2)-targeted antibody...